The Risk of Tuberculosis and TNF-alpha Inhibitors

Acar M., Sutcu M., Salman N., Sourer A.

JOURNAL OF PEDIATRIC INFECTION, vol.11, no.2, 2017 (ESCI) identifier identifier

  • Publication Type: Article / Review
  • Volume: 11 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.5578/ced.201719
  • Journal Name: JOURNAL OF PEDIATRIC INFECTION
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Istanbul University Affiliated: Yes

Abstract

The clinical use of TNF-alpha inhibitors have been increasing in the treatment of autoimmune disorders. The most common anti-TNF-alpha agents on clinical use are ethanercept, infliximab and adalimumab. TNF-alpha is an important mediator in the pathogenesis of tuberculosis, therefore the use of TNFAI increases the risk of tuberculosis. Patients who are on anti-TNF alpha treatment should be carefully evaluated for tuberculosis risk before and during therapy. The recommended screening tools are detailed history, physical examination, tuberculin skin test and/or interferon gamma (IFN-gamma) release assay and chest X-Ray every six months.